

(M.D)

(M.D)^{*}

NEP)
- mg/d (

:

≤ BMI ≤
(HAMD-17)

%

mg/d

mg/d

(% /)

mg/d

mg/d

/ ± /

(% /)

mg/d

mg/d

mg/d

(/ mg/d)

mg/d mg/d

(mg/d)

/ mg/d

(P= /)

mg/d mg/d

:

/ mg/d

(HAMD-17)

[]

% - % -

%

(MDD)

[]

[]

DSM-IV

()

[]

() TCA

[]

[]

$\leq \text{BMI} \leq$

-

- mg

[]

mg/d

mg/d

[]

- mg

(- mg/d)

[]

()

- mg/d

(Hamilton depression rating scale)

[]

[]

[]

[]

[]

[]

%

mg/d

(%)

CBC with (ECG) (LFT)

diff

mg/d



(MDD)

(Moderate)

()% / ()% /

%

(/ ± /)

mg/d

[()]% /

%

)

[](

| | (n) | | (n) | | () |
|-------|-------|-------|-------|-------|-----|
| (n)% | (n) % | (n) % | (n) % | (n) % | |
| / () | / () | / () | / () | () | ≤ |
| / () | / () | / () | / () | / () | - |
| / () | / () | / () | / () | / () | - |
| / () | | | / () | | ≤ |
| () | () | () | / () | / () | (n) |

mg/d (% /)

(% /)

()

()

()

mg/d

()

()

()

| | | | | | | |
|--|--|--|--|--|--|----------|
| | | | | | | () mg/d |
| | | | | | | () |
| | | | | | | () |
| | | | | | | () |
| | | | | | | () |
| | | | | | | () |

mg/d

mg/d

Yan Li

| (n) | (n) mg/d |
|-----|----------|
| | () |
| | () |
| | () |
| | () |
| | () |

%

-

%

mg/d

(%)

Safe

mg/d

[]

/ mg/d

/ mg/d

Vaz

/ mg/d

mg/d

mg/d

mg/d



[]

Szegedi

Wetzel

MDD

(% /)

mg/d

(%)

mg/d

mg/d

mg/d

(%)

mg/d

(% /)


mg/d

(% /)

[]

/ mg/d

Dejonghe
MDD



[1] Angst J. Epidemiology of depression. *Psychopharmacology (Berl)*, 1992; 106 Suppl:S71-4.

[2] Munizza C, Tibaldi G, Bollini P, Pirfo E, Punzo F, Gramaglia F. Prescription pattern of antidepressants in out-patient psychiatric practice. *Psychol Med*, 1995; 25(4):771-8.

[3] Tollefson GD. Antidepressant treatment and side effect considerations. *J Clin Psychiatry*, 1991; 52 Suppl:4-13.

[4] Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. *J Clin Psychopharmacol*, 1994; 14(4):230-40.

[5] Mendels J, Johnston R, Mattes J, Riesenber R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. *Psychopharmacol Bull*, 1993; 29(2):169-74.

[6] Delini-Stula A, Radeke E, Vassout A. Some aspects of the psychopharmacological activity of maprotiline (Ludiomil): effects of single and repeated treatments. *J Int Med Res*, 1978; 6(6):421-9.

[7] Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2002. p.1129.

[8] Sadock BJ, Sadock VA. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 9th ed. Philadelphia: Lippincott Williams & Wilkins, 2002. p.534-5.

[9] Szegedi A, Wetzell H, Angersbach D, Philipp M, Benkert O. Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline. *J Affect Disord*, 1997; 45(3):167-78.

[10] Vaz-Serra A, Figueira ML, Firmino H, Albuquerque AJ, Jara JM, Pestana LC. Multicenter double-blind study of moclobemide and maprotiline. *Clin Neuropharmacol*, 1994; 17 Suppl 1:S38-49.

[11] Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF, Molczadzki M, et al. Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. *Acta Psychiatr Scand*, 1987; 76(5):583-92.

[12] Emrich H M, Berger M, Riemann D, von Zerssen D. Serotoninreuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. *Pharmacopsychiatry*, 1987; 20:60-3.

[13] Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. *Eur Neuropsychopharmacol*, 1993; 3(1):13-21.

[14] Laux G, Beckmann H, Classen W, Becker T. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder. *J Neural Transm Suppl*, 1989; 28:45-52.

[15] Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. *Br J Psychiatry*, 1999; 174:297-303.

[16] Sadock BJ, Sadock VA. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2005. p.943.

[]

mg/d mg/d / mg/d

mg/d

P= / (/ mg/d)

mg/d []

mg/d)

(mg/d

/ mg/d / mg/d

- mg/d

inadequate treatment response. *Acta Psychiatr Scand*, 1997; 95(4):288-96.

[20] de Jonghe F, Swinkels J, Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. *Pharmacopsychiatry*, 1991; 24(1):21-7.

[21] Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. *Eur Neuropsychopharmacol*, 2001; 11(3):227-32.

[17] Li SW, Yan HQ. Maprotiline (Ludiomil) treatment of mental depression--a clinical report of 65 cases. *Proc Chin Acad Med Sci Peking Union Med Coll*, 1989; 4(3):139-41.

[18] Szegedi A, Wetzel H, Angersbach D, Dunbar GC, Schwarze H, Philipp M, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. *Pharmacopsychiatry*, 1997; 30(3):97-105.

[19] Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with